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Abstract
 
Dendritic cells (DCs) and macrophages are professional antigen-presenting cells (APCs) that
play key roles in both innate and adaptive immunity. ChemR23 is an orphan G protein–coupled
receptor related to chemokine receptors, which is expressed specifically in these cell types.
Here we present the characterization of chemerin, a novel chemoattractant protein, which acts
through ChemR23 and is abundant in a diverse set of human inflammatory fluids. Chemerin is
secreted as a precursor of low biological activity, which upon proteolytic cleavage of its
COOH-terminal domain, is converted into a potent and highly specific agonist of ChemR23,
the chemerin receptor. Activation of chemerin receptor results in intracellular calcium release,
inhibition of cAMP accumulation, and phosphorylation of p42–p44 MAP kinases, through the
 
G
 
i 
 
class of heterotrimeric G proteins. Chemerin is structurally and evolutionary related to the
cathelicidin precursors (antibacterial peptides), cystatins (cysteine protease inhibitors), and kini-
nogens. Chemerin was shown to promote calcium mobilization and chemotaxis of immature
DCs and macrophages in a ChemR23-dependent manner. Therefore, chemerin appears as a
potent chemoattractant protein of a novel class, which requires proteolytic activation and is
specific for APCs.
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Introduction
 
DCs and macrophages display phagocytic properties and
are activated by various microorganism-derived molecules
through the family of Toll-like receptors, which trigger the
release of costimulatory molecules, cytokines, and chemo-
kines. Therefore, they play an essential role in innate immu-
nity. These cell populations also constitute the professional
APCs, which are responsible for the mounting of adaptive
immune responses (1, 2). DCs and macrophages are attracted
to infection and inflammatory sites by a variety of factors,
among which chemokines constitute the largest group so
far (3). It has been shown that tremendous functional, mor-
phological, and metabolic diversity exists among these cell
populations. One of these functional differences is the ex-
pression of differential sets of chemoattractant receptors,
which is responsible for the selective recruitment of specific
cell subpopulations according to their lineage, origin, and
maturation state (2).
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Abbreviation used in this paper:
 
 Tig, tazarotene-induced gene.T
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Many tumor types have been demonstrated to attract
macrophages and DCs through the direct or indirect pro-
duction of chemoattractant factors (4, 5). These include a
number of CC chemokines, such as MCP-1. APC recruit-
ment is expected to contribute to the development of an
antitumoral immune response, and such an effect has been
demonstrated in a number of animal studies in which the
forced expression of chemokines, such as RANTES, by tu-
mor cell lines resulted in a decreased pathogenicity of these
cells in vivo. However, a number of studies have demon-
strated that the infiltration of tumors by macrophages and
DCs contributed to their aggressive phenotype by supplying
different classes of factors necessary for tumor cell prolifera-
tion and invasiveness, such as growth and angiogenic fac-
tors, as well as proteolytic enzymes (4, 5). Chemoattractant
factors for DCs and macrophages are therefore frequently
expressed in the tumor microenvironment, and these factors
can play dual roles in the context of tumor progression.
Due to their key roles in immune responses and their in-
volvement in tumor pathogenesis, there is a strong interest
in the identification of new factors contributing to the re-
cruitment of macrophages and DCs. They might indeed on
one hand help to understand better the development of in-
nate and adaptive immune responses, and on the other hand
constitute tools or targets in therapeutic strategies aiming at
modulating the immune responses in situations such as can-
cer, inflammatory diseases, and graft rejection (6, 7).
We have previously described ChemR23 as a human or-
phan G protein–coupled receptor expressed in macro-
phages and immature DCs (8). ChemR23, also known as
Dez in mouse (9), was shown to constitute a minor core-
ceptor for a subset of human immunodeficiency viruses
(10), but no ligand, either natural or synthetic, has been so
far identified for this receptor. ChemR23 is structurally re-
lated to receptors for chemokines and other chemoattrac-
tant molecules and was therefore expected, given its distri-
bution, to specifically attract APCs in response to an
unknown mediator. However, most chemokines and
chemoattractant molecules are characterized by a relatively
poor specificity, as they usually attract a diverse set of leu-
kocyte subpopulations (7, 11). Therefore, ChemR23, by
its specific expression in macrophages and immature DCs,
appeared as a particularly attractive candidate receptor in-
volved in the initiation and early regulation of immune re-
sponses. We have therefore developed an experimental
strategy to identify the ligand of this receptor. Given its
expression pattern, we reasoned that the cognate ligand
should be expressed in inflammatory situations and se-
lected, as sources of potential agonists, a number of patho-
logical situations in which such ligands can be expected to
be generated in large amounts.
 
Materials and Methods
 
Expression of Human ChemR23.
 
The human coding sequence
(Y14838, 8) was cloned into the pcDNA3 (Invitrogen) and
pEFIN3 vectors (Euroscreen) and sequenced. The pEFIN3 con-
struct was transfected using Fugene 6 into CHO-K1 cells express-
 
ing or not G
 
 
 
16 
 
and apoaequorin, and G418-resistant clones were
characterized for ChemR23 (chemerinR) expression by North-
ern blotting. A functional assay based on the luminescence of mi-
tochondrial aequorin (12) was performed as previously described
(13). Results were expressed as relative light units or as percent-
age of the endogenous response to 20 
 
 
 
M ATP.
 
Purification of Human Native Chemerin.
 
1 liter of ascitic fluid
was filtered and loaded (50 ml/run) onto a reverse phase column
(10 
 
  
 
100 mm; Poros 20 R2 beads; Applied Biosystems). A
5–95% CH
 
3
 
CN gradient (6%/min) in 0.1% TFA was applied and
5 ml fractions were collected and assayed for ChemR23 activation.
Active fractions were adjusted to pH 4.8 and applied to a cation-
exchange HPLC column (Polycat 9.6 
 
  
 
250 mm; Vydac) in the
presence of 10% CH
 
3
 
CN, eluted with a 0–1 M NaCl gradient
(10%/min) in acetate buffer, pH 5. Active fractions were desalted
(Ultrafree, cut-off: 10 kD; Millipore), loaded onto a second cat-
ion-exchange column (Polycat 2.1 
 
  
 
250 mm; Vydac), and
eluted with the same buffer (2%/min NaCl gradient). 0.5 ml ac-
tive fractions (desalted) were pooled, diluted eightfold with 0.1%
H
 
3
 
PO
 
4
 
, and loaded onto a C18 column (4.6 
 
  
 
250 mm; Vydac).
A 5–95% CH
 
3
 
CN gradient (0.3%/min) in 0.1% H
 
3
 
PO
 
4 
 
was ap-
plied and individual UV absorption peaks (214 nm) were col-
lected manually and assayed. The active fractions were loaded
onto a second C18 column (2.1 
 
  
 
250 mm; Vydac; 5–95%
CH
 
3
 
CN in 0.1% TFA, 0.3%/min). The peaks were collected
manually and analyzed by mass spectrometry. The use of human
material collected for diagnostic or therapeutic purposes was ap-
proved by the ethical committee of the Université Libre de Brux-
elles Medical School.
 
Cloning and Expression of Human Tazarotene-induced Gene (Tig)-2,
Renamed Chemerin.
 
Human (Q99969) Tig-2 cDNA was am-
plified by PCR from liver cDNA (CLONTECH Laboratories,
Inc.) using human sense (5
 
 
 
-CAGGAATTCAGCATGCGACG-
GCTGCTGA-3
 
 
 
) and antisense (5
 
 
 
-GCTCTAGATTAGCT-
GCGGGGCAGGGCCTT-3
 
 
 
) primers in standard conditions
(94
 
 
 
C for 3 min; 94
 
 
 
C for 90 s, 58
 
 
 
C for 1 min, and 72
 
 
 
C for
90 s, 35 cycles; 72
 
 
 
C for 10 min). The resulting 500-bp fragment
was cloned in pEFIN3 and sequenced. The plasmid was trans-
fected in CHO-K1 cells and G418-resistant clones were charac-
terized by the activity of conditioned medium on chemerinR.
For recombinant chemerin production, cells were grown to 70%
confluence and further incubated with serum-free DMEM-F12,
which was collected after 3 d. The recombinant protein was puri-
fied by filtration through 0.45 
 
 
 
m Millex filters (Millipore) and
separation through a cation-exchange HPLC column (Polycat
9.6 
 
  
 
250 mm; Vydac; 0–1 M NaCl gradient in acetate buffer,
pH 5). The protein concentration in active fractions was deter-
mined after SDS/PAGE by comparison with glutathione 
 
S
 
-trans-
ferase and lysozyme standards after silver staining.
 
Mass Spectrometry Analysis.
 
The active fractions were vacuum
dried, resuspended in 10 
 
 
 
l of 100 mM Tris-HCl, pH 8.7, heated
for 15 min at 95
 
 
 
C, incubated overnight at 37
 
 
 
C with 250 ng
trypsin (Promega), and purified by solid phase extraction (C18
ZipTip; Millipore). The digested peptides were eluted in 1.5 
 
 
 
l
of 70% CH
 
3
 
CN/0.1% TFA onto a metallic MALDI target, dried,
and then mixed in 1.5 
 
 
 
l of matrix mix (2 mg/ml 2,5-dihydroxy-
benzoic acid and 10 mg/ml 
 
 
 
-cyano-4-hydroxycinnamic acid, 2
mM fucose, 5 mM ammonium acetate). For proteic samples ex-
cised from SDS/acrylamide gels, the samples were processed as
previously described (14). For determination of the NH
 
2 
 
terminus
of the recombinant protein, the digested peptides were first sepa-
rated onto a C18 column (250 mm; Vydac, 5–95% CH
 
3
 
CN in
0.1% TFA, 2%/min) and each HPLC fraction was analyzed sepa-T
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rately. Mass spectrometry analysis was performed on a Q-TOF
Ultima Global mass spectrometer equipped with a MALDI
source (Micromass) and calibrated using the monoisotopic masses
of tryptic and chymotryptic peptides from bovine serum albumin.
Ionization was achieved using a nitrogen laser (337 nm beam, 10
Hz) and acquisitions were performed in a V mode reflectron po-
sition. Microsequencing was performed by argon-induced frag-
mentation after selection of the parent ion.
 
Quantitative RT-PCR.
 
ChemerinR and chemerin transcripts
were detected by quantitative RT-PCR (TaqMan) in total or
polyA
 
  
 
RNA samples from human tissues and blood cell popula-
tions obtained commercially (CLONTECH Laboratories, Inc.
and Ambion) or prepared locally (RNeasy Mini Kit; QIAGEN).
Primers were: 5
 
 
 
-GCAGACAAGCTGCCGGA-3
 
  
 
forward,
5
 
 
 
-AGTTTGATGCAGGCCAGGC-3
 
  
 
reverse, and 5
 
 
 
-AAC-
CCGAGTGCAAAGTCAGGCCC-3
 
  
 
as probe for chemerin;
5
 
 
 
-GTCCCAGAACCACCGCAG-3
 
  
 
forward, 5
 
 
 
-AAGAAA-
GCCAGGACCCAGATG-3
 
  
 
reverse, and 5
 
 
 
-TTCGCCTG-
GCTTACATGGCCTGC-3
 
  
 
as probe for chemerinR; and
5
 
 
 
-GAAGGTGAAGGTCGGAGTC-3
 
  
 
forward, 5
 
 
 
-GAAGATG-
GTGATGGGATTTC-3
 
  
 
reverse, and 5
 
 
 
-AGCTCTCCCGCC-
GGCCTCTG-3
 
  
 
as probe for the reference housekeeping gene
GAPDH. Standard curves were run systematically for the three
genes and the transcript copy number of prochemerin and
chemerinR was normalized to the GAPDH transcript copy num-
ber for each sample.
 
Production of Monoclonal Antibodies.
 
BALB/c mice were in-
jected with 100 
 
 
 
g pcDNA-chemerinR as previously described
(15), or with the prochemerin COOH-terminal octapeptide
FSKALPRS. Sera were tested by FACS
 
® 
 
on the CHO-chemer-
inR cell line or by Elisa for the prochemerin peptide, and im-
mune mice were used to generate monoclonal antibodies by stan-
dard hybridoma technology, using the NSO myeloma cell line
(15). The Ig class of selected hybridomas was determined with a
mouse monoclonal antibody isotyping kit (IsoStrip; Boehringer).
 
Binding Assay.
 
ChemR23-expressing CHO-K1 cells were
collected from plates with PBS supplemented with 5 mM
EDTA, gently pelleted for 2 min at 1,000 
 
g
 
, and resuspended in
binding buffer (50 mM Hepes, pH 7.4, 1 mM CaCl
 
2
 
, 5 mM
MgCl
 
2
 
, 0.5% BSA). Competition binding assays were performed
in Minisorb tubes (Nunc) using the 
 
125
 
I-YHSFFFPGQFAFS
peptide as tracer (specific activity: 600 Ci/mmol, 50,000 cpm/
tube), variable concentrations of competitors, and 500,000 cells
in a final volume of 0.1 ml. Total binding was measured in the
absence of competitor and nonspecific binding was measured in
the presence of a 100-fold excess of unlabeled ligand. Samples
were incubated for 90 min at 27
 
 
 
C and then bound tracer was
separated by filtration through GF/B filters presoaked in 0.5%
BSA. Filters were counted in a 
 
 
 
-scintillation counter. Binding
parameters were determined with the PRISM software (Graph-
pad Software) using nonlinear regression applied to a one-site
competition model.
 
Intracellular Cascade Assays.
 
GTP
 
 
 
[
 
35
 
S] binding assays were
performed as previously described (16). Functional parameters
were determined with the PRISM software (Graphpad Soft-
ware) using nonlinear regression applied to a sigmoidal dose-
response model. ERK1/2 activation was assayed by Western
blotting, using an anti–phospho-p42/44 monoclonal antibody
(E10; Cell Signaling Technology) as previously described (13).
All assays were run with or without overnight pretreatment with
100 ng/ml pertussis toxin. It was shown that such pertussis toxin
pretreatment did not inhibit the functional response to ATP in
these cells.
 
Chemotaxis and Ca
 
2
 
  
 
Mobilization Assays on Primary Cells.
 
Monocyte-derived DCs were generated by 50 ng/ml GM-CSF
and 20 ng/ml IL-13 stimulation as previously described (17).
Maturation of DCs was achieved after stimulation with 100 ng/
ml LPS. Macrophages were obtained by incubating monocytes in
Petriperm dishes (Haereus) for 6 d in RPMI supplemented with
10% FCS and 10 ng/ml macrophage colony-stimulating factor.
Cell migration was evaluated using a 48-well microchemotaxis
chamber technique as previously described (18). For Ca
 
2
 
  
 
mobili-
zation assays, monocyte-derived DCs or macrophages (10
 
7 
 
cells/
ml in HBSS without phenol red but containing 0.1% BSA) were
loaded with 5 
 
 
 
M FURA-2 (Molecular Probes) for 30 min at
37
 
 
 
C in the dark. The loaded cells were washed twice, resus-
pended at 10
 
6 
 
cells/ml, kept for 30 min at 4
 
 
 
C in the dark with or
without 10 
 
 
 
g/ml of the blocking 4C7 monoclonal antibody,
and transferred into the quartz cuvette of a luminescence spec-
trometer (LS50B; PerkinElmer). Ca
 
2
 
  
 
mobilization in response to
recombinant chemerin was measured by recording the ratio of
fluorescence emitted at 510 nm after sequential excitation at 340
and 380 nm.
 
Results
 
Isolation and Characterization of Chemerin as the ChemR23
Ligand.
 
We developed, as a screening assay, CHO-K1
cell lines coexpressing human ChemR23, apoaequorin,
and G
 
 
 
16
 
, allowing to test fractions from human inflamma-
tory fluids as well as various porcine and human lymphoid
organs. A biological activity, specific for ChemR23-
expressing cell lines, was detected in fractions resulting
from the reverse phase HPLC fractionation of human ascitic
fluids (secondary to ovary or liver neoplasms) in arthritic
synovial fluid as well as in extracts from human spleen (un-
published data). The activity was purified to homogeneity
from a single batch of ascitis by five successive steps of liq-
uid chromatography (Fig. 1), and the active compound was
Figure 1. Purification of the natural ligand of the ChemR23 receptor
from human inflammatory fluid. (A) First step HPLC fractionation (Poros
column) of human ascitic fluid. The absorbance (AU) and biological activity
on ChemR23 (luminescence in an aequorin-based assay, normalized to
the ATP response, solid bars) are shown. (B) Third step (cation-exchange
column). (C) Fourth step (C18 column). (D) Last step purification of the
active compound (C18 column). The x axis is magnified to focus on the
region of interest.T
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digested by trypsin and analyzed by mass spectrometry (Fig.
2, A and B). Eight peptides were predicted to derive from
the product of the human Tig-2 (Fig. 2 B), covering 91
amino acids out of the 143 amino acid–long sequence of
the Tig-2 gene product (after removal of the predicted sig-
nal peptide; 19). However, the COOH-terminal peptide
(peptide 8) was not tryptic, lacking the last six amino acids
of the predicted protein. This observation indicated that
the active compound might result from the proteolytic
processing of the encoded precursor. The active protein
(137 amino acids, 15,876 D) was named chemerin and
ChemR23, the chemerin receptor (chemerinR). The
cDNA sequence of mouse chemerin was reconstructed
from expressed sequence tags present in the public data-
bases and the predicted primary structure (Fig. 2 C) shares
65% identity with the human polypeptide.
 
Expression and Pharmacological Characterization of Human
Chemerin.
 
Human Tig-2 cDNA was cloned and ex-
pressed in CHO-K1 cells. The bioactive recombinant pro-
tein was purified to homogeneity from conditioned me-
dium and analyzed by mass spectrometry and SDS/PAGE,
which confirmed COOH-terminal truncation after serine
157 (unpublished data). A monoclonal antibody generated
against a peptide (FSKALPRS) corresponding to the pre-
dicted COOH-terminal sequence of the gene product was
Figure 2. Identification of chemerin as the natural ligand of ChemR23,
the chemerin receptor. (A) Monoisotopic peptide mass fingerprinting of the
active fraction on a Maldi Q-TOF mass spectrometer after trypsin digestion.
(B) Sequences corresponding to selected major peaks of the Maldi Q-TOF
mass spectrometer spectrum after trypsin digestion. Peptides 1–7 correspond
to tryptic peptides derived from the Tig-2 gene product (prochemerin),
whereas peptide 8 is not tryptic and corresponds to the COOH-terminal
end of the purified protein. The position of the peptides within this sequence
is given. The sequence of peptides in peaks 3, 5, 7, and 8 was confirmed
by microsequencing. (C) Amino acid sequence alignment of human and
mouse (Protein Data Bank accession no. AK002298) preprochemerin and
human cathelicidin FALL39 precursor. Amino acid identities as compared
with human preprochemerin are boxed. The signal peptides (predicted
for mouse preprochemerin) are in bold lowercase characters and cysteines
are in bold. Cleaved COOH-terminal peptides are in bold italics and under-
lined (predicted by analogy for mouse prochemerin). The location of introns,
which interrupt the gene coding sequences between codons, are indicated
by arrowheads.
Figure 3. Pharmacology of the chemerin receptor. (A) SDS/PAGE of
human recombinant chemerin expressed in CHO-K1 cells and purified
by HPLC. The gel was silver stained and the major band corresponds to a
protein of 18 kD. Mass spectrometry analysis demonstrated the cleavage
of the six COOH-terminal amino acids in this biologically active protein.
(B) Biological activity on chemerinR of human recombinant chemerin
( ) and prochemerin ( ), using the aequorin assay. (C) Competition
binding assay using as tracer an iodinated peptide derived from the
chemerin COOH terminus. Competition was performed with the unlabeled
peptide ( ) or human recombinant chemerin ( ). (D) Concentration-action
curve of human chemerin in a GTP [35S] binding assay, using membranes of
CHO/chemerinR cells. (E) Immunodetection of phosphorylated ERK1/2
in CHO/chemerinR cells after stimulation by human recombinant
chemerin for 2 min. (F) Kinetics of ERK1/ ERK2 activation after stimu-
lation by 10 nM human chemerin. Each experiment was repeated at least
three times.T
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used to purify to homogeneity from CHO-K1–condi-
tioned medium, an unprocessed form of the protein
(prochemerin), which was confirmed by mass spectrometry
to retain the six COOH-terminal amino acids (unpublished
data). The amount of purified recombinant chemerin (Fig.
3 A) and prochemerin (unpublished data) was determined
by comparison with protein standards following SDS/
PAGE and silver staining. It was inferred that  90% of
prochemerin released by CHO-K1 cells was enzymatically
processed into chemerin. Comparison of the biological ac-
tivity of the two purified proteins assayed in parallel on
CHO-K1 cells expressing human chemerinR (Fig. 3 B)
demonstrated that processed chemerin was about 100-fold
more active (EC50: 4.5   0.7 nM, mean   SEM for seven
independent experiments) than unprocessed prochemerin
(EC50: 393   116 nM, mean   SEM for three indepen-
dent experiments). The NH2 terminus of prochemerin and
chemerin was determined by mass spectrometry. A tryptic
peptide (ELTEAQR, 845.45 D) corresponding to amino
acids 21–27 of preprochemerin was identified by sequenc-
ing (unpublished data), confirming the signal peptide cleav-
age site predicted by the SignalP software from Expasy
(http://www.cbs.dtu.dk/services/SignalP/).
ChemerinR is structurally and evolutionary related to
the C5a and C3a receptors, the prostaglandin D2 receptor
CRTH2, and the orphan GPR1 receptor (20). These re-
ceptors, as well as a large set of other characterized and or-
phan receptors, including most chemokine receptors, were
shown to be totally unreactive to purified human chemerin
(unpublished data). The activation of chemerinR by a set
of  200 bioactive molecules, including all currently avail-
able chemokines, C5a, C3a, fMLP, bradykinin, PAF, and
leukotrienes, was also tested. All of these agents were un-
able to promote receptor activation even at concentrations
significantly higher (100 nM or 1  M) than those reported
to activate their own receptors. Therefore, chemerin and
its receptor appear as a specific signaling system, in contrast
to the situation prevailing with inflammatory chemokines
and their respective receptors.
To investigate whether proteolytic activation of pro-
chemerin is performed intracellularly in the secretory
pathway or is an extracellular process potentially regulated
by the activation of extracellular proteases, we tested the
activation of human-purified prochemerin in the medium
of cultured cells and conditioned media. We could show
that human prochemerin can be fully converted into a
form active on chemerinR during the incubation (at 100
nM) in the culture medium of hamster CHO-K1 cells,
simian Cos-7 cells, or human HEK293 cells (unpublished
data), as well as in conditioned media from these cells (Fig.
4 A). These data indicate that prochemerin processing is
performed extracellularly and the active chemerin product
is not degraded further by the proteolytic activity and is
therefore stable in extracellular medium. Although the pro-
tease responsible for this processing is not known, the regu-
lation of this enzyme activity is expected to control the ex-
tracellular generation of active chemerin in vivo.
Pharmacology and Intracellular Signaling of the Chemerin Re-
ceptor. Attempts to develop a binding assay based on the
iodination of full-size chemerin were unsuccessful. How-
ever, structure function analysis of peptides derived from
the COOH terminus of chemerin (unpublished data) al-
lowed the design of a bioactive peptide (YHSFFFPGQ-
FAFS, EC50 of 28 nM on chemerinR-expressing CHO-K1
cells, using the aequorin-based assay) that could be labeled
on its NH2 terminus tyrosine for binding studies. This iodi-
nated peptide was used in a competition binding assay, us-
ing the unlabeled peptide or recombinant chemerin as
competitors (Fig. 3 C). The Ki values were estimated
to 2.5    1.2 nM (pKi: 8.82    0.38) for recombinant
chemerin and 12.1   4.97 nM (pKi: 7.95   0.18) for the
peptide (mean   SEM for three independent experiments).
Figure 4. Expression of human
chemerin and its receptor. (A) Con-
version of 100 nM human recombi-
nant prochemerin in conditioned
medium from hamster CHO-K1
cells. Conversion rate was estimated
by comparing the biological activity
with that of the same molar amount
of purified processed chemerin. (B
and C) Transcripts encoding human
chemerinR (B) and prochemerin
(C) were amplified by quantitative
RT-PCR in a set of human tissues
and cell populations. PBMC, periph-
eral blood mononuclear cells; iDC,
immature DCs. (D and E) The ex-
pression of chemerinR was analyzed
by FACS® in immature (solid line)
and mature DCs (gray area) after
stimulation by LPS (D) or CD40L
(E), using the 1H2 monoclonal anti-
body (IgG2A). Control labeling
(dotted line) was made with an antibody of the same isotype. (F) ChemerinR expression on macrophages was monitored using the 1H2 (thick solid line)
and 4C7 (thin solid line) monoclonal antibodies. Control labeling (dotted line) was made with an antibody of the same isotype.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
Antigen-presenting Cell Recruitment by Chemerin 982
The signaling pathways activated by chemerinR were next
investigated in CHO-K1 cells expressing the human recep-
tor, but not G 16 or apoaequorin (CHO/chemerinR cells).
Receptor activation was tested in a GTP [35S] binding as-
say, using membranes from CHO/chemerinR cells (EC50:
7.8   0.4 nM, mean   SEM for four independent experi-
ments; Fig. 3 D). Stimulation of these cells by human
chemerin at low nanomolar concentrations resulted in the
release of intracellular calcium and inhibition of cAMP ac-
cumulation (unpublished data), as well as phosphorylation
of the p42 and p44 MAP kinases (Fig. 3, E and F). All of
these effects were inhibited by pertussis toxin pretreatment,
demonstrating the involvement of Gi family members. No
activity of recombinant chemerin or prochemerin was ob-
tained in any of these assays on wild-type CHO-K1 cells
(unpublished data).
Expression of Chemerin and Its Receptor. We investi-
gated the presence of prochemerin and chemerinR tran-
scripts in various human tissues and leukocyte populations
by real-time RT-PCR (TaqMan). In addition to immature
DCs, chemerinR transcripts were found primarily in
spleen, lymph nodes, and lung, and at lower levels in a
number of other tissues (Fig. 4 B). Abundant chemerin
transcripts were found in liver, lung, pituitary, and ovary
(Fig. 4 C), and lower levels could be detected in most tis-
sues. Interestingly, however, no expression of chemerin
was found in peripheral blood leukocyte populations.
Monoclonal antibodies generated against human chemer-
inR by genetic immunization (15) and characterized by
FACS® on CHO-K1 cell lines expressing the receptor (un-
published data) were used to confirm the presence of the
receptor at the surface of DCs and macrophages. High lev-
els of chemerinR immunoreactivity were found on mono-
cyte-derived immature DCs, and chemerinR was down-
modulated after maturation of the cells as a result of LPS or
CD40L stimulation (Fig. 4, D and E). Similarly, chemer-
inR immunoreactivity was observed at the surface of
monocyte-derived human macrophages (Fig. 4 F). The
ability of anti-chemerinR antibodies to block receptor acti-
vation by chemerin was investigated using the aequorin as-
say on chemerinR-expressing CHO-K1 cells. We found
that two antibodies (4C7 and 1H2) were able to efficiently
inhibit calcium mobilization promoted by recombinant
chemerin in a concentration-dependent manner (Fig. 5 A).
To investigate whether chemerin is frequently generated
in pathological situations in humans, we fractionated a set
of inflammatory fluids and assayed the chemerin content by
measuring the biological activity of the fractions on
chemerinR as compared with a standard curve made with
purified recombinant chemerin. Significant levels of active
chemerin, well within the active range (33–358 ng/ml,
corresponding to 2–23 nM), were found in the majority of
board analysis investigates chemotactic versus chemokinetic effects of
chemerin on macrophages. (G) Ca2  flux in macrophages in response to 30
nM recombinant chemerin (arrow). (H) The same experiment after 30 min
preincubation of the cells with 10  g/ml of the 4C7 monoclonal antibody.
Figure 5. Biological activity of chemerin on primary cells. (A) Inhibition
of the functional response of CHO-K1 cells expressing the chemerinR
(aequorin assay) by the 4C7 anti-chemerinR monoclonal antibody. The
cells were preincubated for 30 min at room temperature with various
amounts of the 4C7 antibody before stimulation by 10 nM recombinant
chemerin. The data were normalized according to the response in the
absence of antibody (100%) and in the absence of agonist (0%). (B) Chemo-
taxis of human immature DCs by recombinant chemerin. Results are
expressed as the mean   SD (n   3) and are representative of three donors.
(C) 10 pM chemerin-induced DC migration was inhibited by 3  g/ml
pertussis toxin pretreatment of the cells, as well as by preincubation of the
cells with 10  g/ml of the 4C7 monoclonal antibody. Checkerboard
analysis investigates chemotactic versus chemokinetic effects of chemerin
on DCs. 10 pM human chemerin was added to the lower and/or upper
chamber of the chemotaxis device. 10 nM of the chemokine RANTES
was used as a positive control in the experiments. (D) Ca2  flux in mono-
cyte-derived DCs in response to 30 nM recombinant chemerin (arrow).
(E) The same experiment after 30 min preincubation of the cells with 10
 g/ml of the 4C7 monoclonal antibody. (F) Chemerin-induced macro-
phage migration (10 and 100 pM) and its inhibition by 3  g/ml pertussis
toxin pretreatment and 10  g/ml 4C7 monoclonal antibody. Checker-T
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ascitic fluids resulting from ovary cancer, but also in ascitic
fluids resulting from a liver cancer and from an ovary hy-
perstimulation syndrome, as well as in a pool of synovial
fluids from arthritic patients (Table I). Interestingly, active
chemerin was not detected in synovial fluids pooled from
patients with osteoarthritis (Table I), nor in fractions from
human hemofiltrate (unpublished data), demonstrating that
its presence is linked to inflammatory situations.
Biological Activity of Chemerin. The biological function
of chemerin was further investigated on leukocyte popula-
tions. In accordance to the coupling of human chemerinR
through the Gi class of G proteins, its structural relatedness
to chemoattractant receptors, and its expression in APCs,
we showed that chemerin acted as a chemotactic factor
for these cells. DCs and macrophages were differentiated
in vitro from human monocytes. Human recombinant
chemerin promoted in vitro migration of macrophages and
immature DCs (Fig. 5, B, C, and F), whereas no chemo-
taxis of mature DCs was observed (unpublished data).
Maximal chemotactic responses were obtained for concen-
trations of 100 pM to 1 nM, according to the batch of
recombinant chemerin. Such bell-shaped chemotactic re-
sponse, with a maximum corresponding to concentrations
below the EC50 observed in other functional assays, is typi-
cally observed for other chemotactic factors such as chemo-
kines. The effect was completely abolished after treatment
with pertussis toxin (Fig. 5, C and F), demonstrating the
involvement of the Gi class of G proteins. Migration of
macrophages and DCs was also inhibited by the anti-
chemerinR monoclonal antibody 4C7 (Fig. 5, C and F)
without affecting RANTES-induced cell migration, dem-
onstrating that the effect is specifically mediated by the
chemerinR. A checkerboard analysis showed that when
equal concentrations of chemerin were present in both the
lower and upper wells, no significant increase in cell migra-
tion was observed (Fig. 5, C and F). Thus, the migration of
macrophages and immature DCs induced by chemerin is
essentially a chemotactic effect rather than chemokinesis.
We also investigated whether recombinant chemerin could
induce Ca2  mobilization in APCs. As expected, intracellu-
lar Ca2  levels increased in immature DCs in response to
recombinant chemerin (Fig. 5 D), whereas the 4C7 anti-
body inhibited the Ca2  response (Fig. 5 E). Similar obser-
vations were made for macrophages (Fig. 5, G and H).
Discussion
Orphan G protein–coupled receptors have proved over
the past few years to constitute key tools allowing the iden-
tification of new extracellular pathways. Our work repre-
sents one of the few examples so far, in which the natural
ligand of an orphan receptor has been purified from a hu-
man natural source, using the receptor as a bioassay. This
approach has led to the discovery of new ligands such as
nociceptin/orphanin FQ, orexins, or ghrelin, which have
since taken a growing importance in various aspects of
physiology (21–23). We have focused in this work on
ChemR23 because of its relatedness to chemoattractant re-
ceptors and its unique expression pattern among leukocyte
populations, being specific to macrophages and immature
DCs, the two major classes of APCs involved both in in-
nate and adaptive immune responses.
We have identified a novel protein, chemerin, as the
natural ligand of ChemR23, renamed the chemerin recep-
tor or chemerinR. Chemerin is encoded by a poorly char-
acterized gene (Tig-2), previously shown to be overex-
pressed in nonlesional psoriatic skin and at lower levels in
psoriatic lesions, and to be up-regulated by the synthetic
retinoid tazarotene in these lesions (19). Induction of this
gene was also shown in the bone stromal cell line ST2 after
stimulation by 1,25-dihydroxy-vitamin D3 and dexa-
methasone (24). However, no specific function has been
proposed so far for this gene, which was not predicted pre-
viously to encode a secreted protein, although the presence
of a signal peptide is unambiguously predicted by classical
algorithms. We have demonstrated here that prochemerin
is indeed secreted, but that its activation into chemerin re-
quires a specific proteolytic processing. Therefore, the gen-
eration of chemerin appears to be regulated at two levels.
Table I. Bioactive Chemerin Concentration in Human Samples
Sample Pathology Chemerin (ng/ml)
1 Ovary Carcinoma 74
2 Ovary Carcinoma 73
3 Ovary Carcinoma 104
4 Ovary Carcinoma 92
5 Ovary Carcinoma n.d. ( 10)
6 Ovary Carcinoma 82
7 Ovary Carcinoma 103
8 Ovary Carcinoma 43
9 Ovary Carcinoma 87
10 Ovary Carcinoma n.d. ( 10)
11 Ovary Carcinoma 90
12 Ovary Carcinoma 33
13 Ovary Carcinoma 57
14 Ovary Carcinoma 87
15 Ovary Carcinoma 62
16 Ovary Carcinoma 37
17 O.H.S. 116
18 Arthritis 358
19 Osteoarthritis n.d. ( 1)
The amount of chemerin in ascitic (samples 1-17) and synovial (sam-
ples 18 and 19) fluids was estimated after two fractionation steps, by
assaying the fractions on chemerinR-expressing cells using the
aequorin-based assay and a standard curve made with purified recombi-
nant human chemerin. Synovial fluids from arthritis and osteoarthritis
patients were pooled for measurement after centrifugation. O.H.S.,
ovarian hyperstimulation syndrome; n.d., not detectable (the limit of
detection in the assay conditions is given).T
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First, it is transcriptionally regulated, and this regulation ap-
pears to vary according to cell types and tissues. Second,
the processing of prochemerin is mediated by a so far un-
characterized extracellular protease, and this proteolytic ac-
tivity is likely regulated as well, according to the extracellu-
lar matrix remodeling status of the tissue.
The COOH-terminal processing of prochemerin, i.e.,
proteolytic cleavage after serine 157, is reminiscent of the
situation in other proteins that share a similar fold. Indeed,
database searches identified cathelicidins, cystatins, and re-
lated proteins such as the bradykinin precursor kininogen, as
the closest structural relatives of prochemerin. The sequence
of the human cathelicidin FALL-39 precursor is displayed in
Fig. 2 C. Although primary structure similarity is low, a pat-
tern of conserved cysteines is shared across the various pro-
teins. In addition, the number and location of introns is
strictly conserved within the gene structure of prochemerin,
cathelicidins, cystatins, and kininogens, further demonstrat-
ing their evolutionary relationship. This is illustrated for the
FALL-39 gene in Fig. 2 C. Prochemerin is therefore likely
to adopt the same fold as chicken cystatin (Protein Data
Bank accession no. 1CEW). However, prochemerin con-
tains six cysteines instead of four in procathelicidins and cys-
tatins, suggesting the presence of a third disulfide bond.
Cathelicidins are secreted as propeptides that require pro-
teolytic processing to generate a COOH-terminal peptide
endowed with bactericidal properties (25). Both the
COOH-terminal peptide and the structured NH2-terminal
(cystatin-like) domain have been shown to display chemo-
tactic properties for leukocytes, properties which involve G
protein–coupled receptors (26, 27). In addition, bradykinin,
a well known G protein–coupled receptor agonist, is also
released by the COOH-terminal processing of its precursor,
kininogen, which is made of three cystatin-like modules
(28). Therefore, chemerin belongs to a large family of evo-
lutionary related protein precursors, which after proteolytic
processing, generate peptides and proteins involved in in-
nate and adaptive immune responses.
Chemerin is a potent chemoattractant of immature DCs
and macrophages, acting at concentrations similar to that of
most chemokines (10 pM to 1 nM). The use of neutraliz-
ing antibodies allowed the demonstration of the involve-
ment of the chemerinR in this process. Nanomolar con-
centrations of active chemerin were found in a large
proportion of ascitic fluids secondary to ovarian carcinomas
(Table I). Such ascitic fluids are known to display a strong
inflammatory component, and bioactive concentrations of
various chemokines have been described in the same sam-
ples (29). Bioactive chemerin was also recovered in other
samples well known to contain high levels of inflammatory
mediators. The expression pattern suggests that this new
system is involved in many human diseases characterized by
strong inflammatory responses. Previous demonstrations of
prochemerin expression suggest an involvement in psoriasis
(18) as well as in the control of bone remodeling by the
macrophage-related osteoclast population (24). Therefore,
this novel protein and its receptor constitute interesting
candidates as therapeutic targets for future development.
The development of knockout models for the chemerin
and its receptor gene, currently in progress, will help fur-
ther delineate the role of this system.
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